logo
  

Novavax's Prototype Vaccine Shows Broad Immune Responses Incl. Against Omicron And Other Variants

Novavax Inc.'s (NVAX) prototype vaccine (NVX-CoV2373) demonstrated broad immune responses including against Omicron and other circulating variants. Pre-clinical data demonstrated that boosting with the company's Omicron or prototype vaccine induced immune response against Omicron variants, including BA.4/5, the company said in a statement.

The company said it participated in the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee's or VRBPAC meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the U.S. beginning this fall.

During the meeting, Novavax highlighted data showing that the structural features of Novavax' protein-based COVID-19 vaccine, enhanced by the Matrix-M adjuvant, displayed epitopes across both the original strain and emerging variants, contributing to the generation of broadly cross-reacting antibodies.

Additional data from Phase 2 and Phase 3 trials, as well as in vitro data on neutralizing antibodies and receptor inhibition from trial participants, showed cross-reactivity with all variants tested, particularly following booster doses.

According to the company, preclinical trial data showed that boosting with either the prototype (NVX-CoV2373), Omicron BA.1 (NVX-CoV2515), or bivalent vaccine generated antibody levels that were consistent with dosing regimens in the Phase 3 clinical trials. While boosting with the prototype covers all strains, providing an Omicron booster enhances immunity to related Omicron sub-variants.

Boosting with a bivalent vaccine containing prototype and Omicron BA.1 showed no advantages in any of the responses compared to boosting with BA.1 alone.

A clinical trial is ongoing with results anticipated in September and product availability expected in fourth quarter.

Novavax submitted a request to the FDA for Emergency Use Authorization in January 2022. The VRBPAC Committee voted 21 to 0 with one abstention on June 7, 2022, to recommend that the FDA grant Emergency Use Authorization for NVX-CoV2373 for individuals aged 18 years and over.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The UK government decided to abandon its plan to scrap the 45 percent tax rate, which was announced just 10 days before, after coming under severe criticism for such a relaxation for the high earners at the time of rising living costs. Russia's manufacturing activity grew at the fastest pace in three-and-a-half years in September, supported by increases in production and new orders, survey data from S&P Global showed on Monday. The factory Purchasing Managers' Index posted 52.0 in September, up from 51.7 in August. A score above... India's manufacturing sector growth slowed moderately in September but the overall growth remained robust, survey data published by S&P Global showed on Monday. The manufacturing Purchasing Managers' Index fell to 55.1 in September from 56.2 in August. The score was also below economists' forecast...
Follow RTT